UnitedHealth Group is a leading diversified health and well-being company that provides a wide range of health care products and services. The company operates through two main segments: UnitedHealthcare, which offers health insurance and health services to individuals and businesses, and Optum, which delivers pharmacy care, health management, and technology solutions. UnitedHealth Group focuses on enhancing health care access, improving health outcomes, and optimizing costs through integrated care solutions and data-driven insights. With a commitment to innovation and quality, the company aims to help people live healthier lives while making the health care system work better for everyone. Read More
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026, soundly beating Wall Street’s expectations. The healthcare giant accompanied its earnings beat with a bold 2026 financial forecast, projecting
As the financial world settles into early 2026, all eyes have turned toward Omaha, where Berkshire Hathaway (NYSE:BRK.B) has just cemented its status as the world’s most formidable financial fortress. In a period defined by market volatility and shifting interest rate expectations, Berkshire’s recent financial disclosures
The U.S. labor market has defied expectations of a late-cycle collapse, entering 2026 in a state of "fragile equilibrium" that has calmed recessionary fears on Wall Street. Following a turbulent 2025 characterized by slowing hiring and cooling wage growth, the latest data for December 2025 and early January 2026
The United States labor market entered 2026 not with a bang, but with a whisper. The December jobs report, released by the Bureau of Labor Statistics on January 9, 2026, revealed a startlingly low addition of just 22,000 jobs. This figure represents the narrowest margin of growth in the
As the calendar turned to January 2026, the S&P 500 carved out a historic milestone, surmounting the psychological 7,000 level for the first time. This rally, coming off the heels of a robust 2025, initially appeared to be a continuation of the artificial intelligence-driven "melt-up" that has defined
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
UnitedHealth stock has certainly taken a beating over the past year. The shares have fallen down roughly 36% to 50%, depending on the measurement period. Yet, Bernstein analyst Lance Wilkes has named it his “top healthcare pick for 2026.
As the calendar turns toward late January 2026, a familiar sense of dread has returned to the halls of Congress and the screens of global investors. After the record-breaking 43-day shutdown that paralyzed the federal government in late 2025, a new "funding cliff" is fast approaching on January 31. This time, however, the uncertainty is [...]
In a week defined by dramatic market divergence, the U.S. stock market has undergone one of its most significant structural shifts in years. As of January 16, 2026, a massive migration of capital is underway, moving from the high-flying technology giants that dominated the previous three years into "old
UnitedHealth stock sinks as President Trump says he will get rid of insurance brokers and corporate middlemen. Bernstein still recommends buying UNH shares at current levels.
As we enter the first weeks of 2026, the narrative of a stock market dominated by a handful of tech giants has finally given way to a more balanced and resilient economic landscape. For the first time since the post-pandemic recovery, the S&P 500 index is no longer relying
A Senate committee investigation reportedly suggests UnitedHealth used aggressive tactics to boost Medicare payments. Here’s how you should play UNH stock following these new accusations.
The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative progress and pharmaceutical innovation. On January 8, 2026, the U.S. House of Representatives passed a crucial bill
